Johnson & Johnson’s multiple myeloma treatment approved by US FDA

Johnson & Johnson (J&J) has received US FDA approval for its multiple myeloma treatment, Tecvayli plus Darzalex Faspro, for adults with relapsed or refractory multiple myeloma (RRMM). This approval, based on phase 3 data showing significantly improved progression-free survival and overall survival rates of 83% after three years, offers a potential new standard of care as early as second-line treatment. The treatment primes and activates the immune system to eradicate myeloma cells, providing a novel approach for patients who often experience multiple relapses.